NCT00948987

Mechanism Based Resistance to Aspirin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 400 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.

Conditions

• Aspirin Resistance
• Pharmacological Aspirin Non-responsiveness

Interventions

Type	Name	Description
DRUG	Aspirin	325 mg enteric coated single dose p.o.

Timeline

• Start date: 2004-09-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2009-07-30
• Last updated: 2009-10-15